Search

Background Heart transplant has become the gold standard therapy for end-stage heart failure. Short- and long-term outcomes after orthotopic heart transplant have been excellent. Many patients with heart failure manifest hepatic failure as a result of a chronically elevated central venous pressure. Concomitant hepatic failure has been a contraindication to heart transplant in most centers. A few select institutions are currently performing combined heart-liver transplantation to treat dual organ failure. The outcomes after dual organ transplant are largely unknown, with limited data from a few select centers. We undertook this study to analyze our large experience with combined heart-liver transplant and determine the short-term and long-term outcomes associated with this procedure. Methods We have performed 1,050 heart transplants at our center to date. Of these patients, 26 underwent combined heart and liver transplant (largest single-center experience). We reviewed demographic, perioperative, and short- and long-term outcomes after this combined procedure. Results All 26 patients underwent successful dual organ transplant, without any episodes of primary graft dysfunction. Average length of intensive care unit stay was 10 ± 5 days, and average hospital stay was 25 ± 11 days. Kaplan-Meier analysis demonstrated excellent short-term survival (1 year, 87% ± 7%) and long-term survival (5 years, 83% ± 8%). Interestingly, only 3 patients (11%) demonstrated any evidence of rejection long-term by myocardial biopsy, suggesting that concomitant hepatic transplantation may provide immunologic protection for the cardiac allograft. Conclusions We present the largest single-center series of combined heart and liver transplant. This dual organ strategy is highly feasible, with excellent long-term survival. Concomitant liver transplant may confer immunologic protection for the cardiac allograft.

severe PH, were obtained retrospectively. Changes after 3 months from baseline ( ) were compared between groups using Ttest. Results: At baseline, there were no differences between groups. After three months, SIL-treated and SIL-naive groups differed in PVR (-1,9 vs 0.2, p 0.004), cardiac output (0.55 vs -0.1 p 0.02) stroke volume: (8,91 vs -2,58 p 0,01) mean PA pressure (-5,12 vs 0,87 p 0.07) transpulmonary gradient (-4,81 vs 1,07 p 0,01)No change was observed on PAWP and right atrial pressure. SIL-treated subjects experienced improvement of NYHA class (0.3 vs 0.1,p ...) and had stable weight, in conrast to sild-naive patients.